BURLINGTON, Vt.–(BUSINESS WIRE)–June 2, 2003–Triosyn Corp., a company focused on the development of advanced microbiocidal compounds, announced today that it has raised an additional $4 million inprivate equity financing, bringing the total of this round to $12 million.<\/p>\n
The additional financing comes entirely from members of Triosyn’s existing investor group, made up of SL Ventures, CDP Capital – Technology Ventures, a member of CDP Capital, BDC Venture Capital, and Innovatech du Grand Montreal. This subsequent commitment comes as a result of Triosyn’s achievement of all its milestones, including the realization of revenue targets, build-up of management team and staff, as well as regulatory approvals.<\/p>\n
“We are encouraged that our existing investors have decided to increase their participation in Triosyn Corp., as this demonstrates their confidence in our core Triosyn(R) compound and our ability to apply it to a variety of commercial, military and healthcare applications,” commented Pierre Jean Messier, Founder, President and CEO of Triosyn.<\/p>\n
Triosyn intends to use the additional funding to accelerate the commercialization of its first group of broad-spectrum microbiocidal products. These products have demonstrated efficiency against spores, bacteria, fungi and viruses in studies by national and international military departments, as well as world-renowned health science laboratories. A major focus of the commercialization effort will be on a facemask purification media containing the Triosyn biocidal resin polymer, which will be manufactured and distributed exclusively in Europe, North and South America by Bacou-Dalloz, a world leader in air filtration products. The addition of Triosyn(R) to air filtration will finally provide the necessary bio-active protection against microbiological entities.<\/p>\n
“We believe there is tremendous potential for Triosyn and its product portfolio. Having met the milestones we set, the Company has proved to us that it can deliver results to target, and we look forward to the next developments in the pipeline,” said Ivan Roch of CDP Capital -Technology Ventures.<\/p>\n
“Triosyn(R) is a unique, non-toxic compound that will improve health and safety in a broad range of products as it kills all disease-causing microorganisms in fluid, air or on surfaces,” continued Mr. Messier. “As demonstrated in depth by third-party laboratories across the globe, Triosyn is a vast improvement over existing biocidal agents due to its efficacy, versatility and non-toxic demand-release delivery mechanism.”<\/p>\n
About Triosyn:<\/p>\n
Triosyn Corp. has developed a novel technology to kill disease-causing microorganisms and to treat microbial infections. Its core technology, Triosyn(R) resin, is an iodinated polymer that interacts with and kills all microorganisms on contact, and due to a proprietary demand-release delivery mechanism provides enhanced safety to humans and the environment. The basic formulation of Triosyn(R) has been registered with the EPA and further registration of Triosyn(R) applications are in process.<\/p>\n
Triosyn(R) is versatile and effective in fluid, air, surface and dermatological applications. The Company has developed a diversified portfolio of products in air filtration, water purification, paints and coatings, barrier textiles and protective clothing, dermatological preparations and wound treatments. These products offer enhanced health and safety profiles and have a wide array of commercial, military and healthcare applications. Triosyn’s offices are located in Burlington, Vermont, with research and development laboratories in Montreal, Canada. For more information, please visit www.triosyn.com.<\/p>\n
About CDP Capital – Technology Ventures<\/p>\n
CDP Capital – Technology Ventures, a member of CDP Capital, invests in innovative companies with promising leading-edge technologies. It also develops partnerships with venture capital funds in Canada, the United States and Europe. Through its portfolios I and II, CDP Capital – Technology Ventures has invested, in 2002, in about 53 companies and investment funds in biotechnology and life sciences, information technologies and industrial technologies. The market value of the total assets under management by CDP Capital – Technology Ventures is almost CA$1.0 billion (US$0.63 billion). Visit www.cdpcapital.com\/technologyventures for more information. CDP Capital, the largest asset manager in Canada, has close to CA$130 billion (US$82.05 billion) in total assets under management and oversees the activities of CDP Capital – World Markets, CDP Capital – Private Equity and CDP Capital – Real Estate Group. For more information: www.cdpcapital.com<\/p>\n
About Innovatech<\/p>\n
Innovatech du Grand Montreal, specializes in risk management and is an expert in technologically innovative investments and “start-up successes”. Innovatech concentrates its investments in dynamic sectors such as computer and telecommunication technologies, health sciences and advanced technologies (www.innovatech.qc.ca)<\/p>\n
About BDC Venture Capital<\/p>\n
BDC Venture Capital is a major venture capital investor in Canada, active at every stage of a company’s development cycle, from start-up through expansion. Its focus is on technology-based businesses with high growth potential that are positioned to become dominant players in their markets. (http:\/\/www.bdc.ca\/venturecapital)<\/p>\n","protected":false},"excerpt":{"rendered":"
BURLINGTON, Vt.–(BUSINESS WIRE)–June 2, 2003–Triosyn Corp., a company focused on the development of advanced microbiocidal compounds, announced today that it has raised an additional $4 million inprivate equity financing, bringing the total of this round to $12 million. The additional […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-176","post","type-post","status-publish","format-standard","hentry","category-hedgeco-news"],"_links":{"self":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/posts\/176","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/comments?post=176"}],"version-history":[{"count":0,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/posts\/176\/revisions"}],"wp:attachment":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/media?parent=176"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/categories?post=176"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/tags?post=176"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}